Update notification · 03.09.2026
Supply shortage Germany: Aminoven infant 10%
Affected country: Germany · Reported period: 19.02.2026 – 31.12.2026 · Active ingredient: Acetylcystein; Alanin; Arginin; Glycin; Histidin; Isoleucin; L-Äpfelsäure; Leucin; Lysinacetat; Methionin; N-Acetyltyrosin (Ph.Eur.); Phenylalanin; Prolin; Serin; Taurin; Threonin; Tryptophan; Valin
Notice context
A supply shortage has been recorded for Aminoven infant 10% in Germany. The stated reason is “Increased demand”. The notice concerns the active ingredient Acetylcystein; Alanin; Arginin; Glycin; Histidin; Isoleucin; L-Äpfelsäure; Leucin; Lysinacetat; Methionin; N-Acetyltyrosin (Ph.Eur.); Phenylalanin; Prolin; Serin; Taurin; Threonin; Tryptophan; Valin and is identified as hospital-relevant.
This information describes the reported supply status and is not medical or pharmaceutical treatment advice. Availability, alternatives and further measures must be assessed for each individual case by the responsible pharmaceutical market participants.
Official shortage notice for Germany. Responsibility and update procedures follow the information supplied by the relevant authority.
Check the official notice list →Implications for procurement and the supply chain
The notice for Aminoven infant 10% is a supply signal concerning Acetylcystein; Alanin; Arginin; Glycin; Histidin; Isoleucin; L-Äpfelsäure; Leucin; Lysinacetat; Methionin; N-Acetyltyrosin (Ph.Eur.); Phenylalanin; Prolin; Serin; Taurin; Threonin; Tryptophan; Valin in Germany. The published reason “Increased demand” determines which data should be verified first.
When demand rises, available stock, open orders, allocations, actual stock coverage and the confirmed replenishment date should be checked separately.
Decision route for this supply case
- Confirm the notice, product identity, period and actual demand with the primary source and accountable market participants.
- Assess allocations, coverage, replenishment and a lawful product-specific buffer stock separately.
- Document release, stock status, GDP evidence, warehousing and transport process, and escalation responsibility.
Inter-Pharma can structure the B2B case, potential sourcing and warehousing routes, and operational implementation. Clinical decisions, regulatory permissibility, product release and actual availability remain with the accountable parties.
Request a structured supply review →Operational shortage resilience: GDP warehousing and pharmaceutical storage
For demand peaks, a lawful, product-specific safety or buffer stock for Aminoven infant 10% can support operational coverage.
Inter-Pharma combines GDP-oriented pharmaceutical storage in Czechia with batch and expiry control, FEFO, stock status, picking and dispatch preparation in its own Cheb operation.
Storage at 15–25 °C or any 2–8 °C requirement is derived solely from the product specification and confirmed for the project.
Operational checks for this notice
- Match product identity using PZN 08452629, 10382161, active ingredient, strength, dosage form and pack.
- Confirm the reported status and the period 19.02.2026 to 31.12.2026 with the primary source and potential suppliers.
- Prioritise hospital demand, supply relevance and the escalation route with the accountable market participants.
- Clarify temperature, batch, expiry, stock status, recipient authorisation and GDP evidence before cross-border supply.
Relevant services and specialist pages
The following B2B topics are particularly relevant when handling a shortage involving Aminoven infant 10%: